Physician profile
Heather North
NPI 1780780668
$8,084.96
in general payments reported to CMS, 2019-2025
31 companies · $749 in 2025
The $749 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,566 · 2020: $1,411 · 2021: $1,156 · 2022: $1,856 · 2023: $282 · 2024: $63.75 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,025 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.95 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,259.62 | 2019-2025 | Evenity, Otezla, Enbrel |
| Abbvie INC. | $1,739.05 | 2019-2025 | |
| Janssen Biotech, INC. | $523.39 | 2019-2025 | Tremfya |
| Pfizer INC. | $500.63 | 2019-2023 | |
| Ucb, INC. | $379.14 | 2019-2022 | |
| Genzyme Corporation | $333.24 | 2020-2025 | |
| Lilly USA, LLC | $308.75 | 2019-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $290.90 | 2019-2024 | |
| Glaxosmithkline, LLC. | $287.74 | 2019-2023 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $221.22 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $158.82 | 2021-2023 | Lupkynis |
| Janssen Scientific Affairs, LLC | $147.49 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.39 | 2019-2022 | |
| Radius Health, INC. | $118.30 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $79.70 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $79.63 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $72.96 | 2019-2020 | |
| Genentech USA, INC. | $68.33 | 2019-2020 | |
| Celgene Corporation | $52.68 | 2019 | |
| Octapharma USA, INC. | $51.15 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $50.87 | 2019 | |
| Pacira Therapeutics, INC. | $43.56 | 2019 | |
| Medexus Pharma, INC. | $37.96 | 2019 | |
| Horizon Therapeutics Plc | $37.09 | 2019-2021 | |
| Bioventus LLC | $35.78 | 2019 | |
| Scilex Pharmaceuticals INC. | $18.98 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.64 | 2020 | |
| Hikma Pharmaceuticals USA | $14.88 | 2019 | |
| Ani Pharmaceuticals, INC. | $14.07 | 2022 | |
| Mallinckrodt Hospital Products INC. | $12.59 | 2020 | |
| Antares Pharma, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather North listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.